Tiplimotide (NBI-5788) is an analog of an immunodominant epitope of myelin basic protein (MBP) for the potential intravenous treatment of multiple sclerosis (MS). NBI-5788-reactive T-cell lines generated from NBI-5788-treated patients exhibited an increased frequency of cross-reactivity with MBP peptide 83-99 compared with NBI-5788-reactive lines from control MS patients. Cytokine secretion by APL-reactive T-cell lines from NBI-5788-treated MS patients was more frequently T-helper 2-like compared with T-cell lines from untreated MS patients. Not every patient exhibited a robust T-cell response to NBI-5788 administration. Tiplimotide had been in phase II clinical trial for the treatment of multiple sclerosis. However, this development was discontinued.